Stock 4548 SEIKAGAKU CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

Financials Seikagaku Corporation

Equities

4548

JP3414000004

Pharmaceuticals

Delayed Japan Exchange
Other stock markets
 02:00:00 2024-04-26 am EDT 		5-day change 1st Jan Change
737 JPY 0.00% Intraday chart for Seikagaku Corporation -0.41% -3.15%
Apr. 08 Ferring Pharmaceuticals Inc. Presents Pivotal Phase 3 Efficacy and Safety Data for Investigational Treatment, SI-6603, in Lumbar Disc Herniation at ASIPP 2024 CI
2023 Seikagaku Corporation Reports Earnings Results for the Full Year Ended March 31, 2023 CI

Valuation

Fiscal Period: March 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 67,628 63,638 58,348 49,215 44,521 40,211 - -
Enterprise Value (EV) 1 51,308 43,131 32,736 17,433 16,132 15,365 14,038 13,515
P/E ratio 30.2 x -5.87 x 13.7 x 13.2 x 20.1 x 15.5 x 22.8 x 14.9 x
Yield 2.17% 2.3% 2.32% 3.43% 3.2% 3.53% 3.53% 3.53%
Capitalization / Revenue 2.38 x 2.22 x 2.11 x 1.41 x 1.33 x 1.11 x 1.17 x 1.11 x
EV / Revenue 1.81 x 1.51 x 1.18 x 0.5 x 0.48 x 0.43 x 0.41 x 0.37 x
EV / EBITDA 13.2 x 11.5 x 14 x 3.14 x 4.69 x 4.8 x 4.32 x 3.11 x
EV / FCF 28.3 x 6.57 x -51.6 x - -53.8 x -3.78 x 6.9 x 12.1 x
FCF Yield 3.53% 15.2% -1.94% - -1.86% -26.5% 14.5% 8.26%
Price to Book 0.93 x 1.06 x 0.92 x 0.74 x 0.66 x 0.59 x 0.58 x 0.57 x
Nbr of stocks (in thousands) 56,404 56,416 56,430 56,246 54,761 54,560 - -
Reference price 2 1,199 1,128 1,034 875.0 813.0 737.0 737.0 737.0
Announcement Date 5/10/19 5/19/20 5/13/21 5/13/22 5/12/23 - - -
1JPY in Million2JPY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: March 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 28,384 28,642 27,662 34,851 33,456 36,100 34,500 36,200
EBITDA 1 3,879 3,738 2,338 5,545 3,441 3,200 3,250 4,350
EBIT 1 977 1,960 1,530 4,495 2,114 1,300 1,400 2,500
Operating Margin 3.44% 6.84% 5.53% 12.9% 6.32% 3.6% 4.06% 6.91%
Earnings before Tax (EBT) 1 2,859 -9,543 3,024 5,395 3,069 2,900 1,900 3,000
Net income 1 2,244 -10,839 4,262 3,733 2,236 2,600 1,760 2,700
Net margin 7.91% -37.84% 15.41% 10.71% 6.68% 7.2% 5.1% 7.46%
EPS 2 39.76 -192.2 75.54 66.32 40.49 47.70 32.30 49.50
Free Cash Flow 1 1,811 6,561 -634 - -300 -4,070 2,035 1,117
FCF margin 6.38% 22.91% -2.29% - -0.9% -11.27% 5.9% 3.09%
FCF Conversion (EBITDA) 46.69% 175.52% - - - - 62.62% 25.68%
FCF Conversion (Net income) 80.7% - - - - - 115.62% 41.37%
Dividend per Share 2 26.00 26.00 24.00 30.00 26.00 26.00 26.00 26.00
Announcement Date 5/10/19 5/19/20 5/13/21 5/13/22 5/12/23 - - -
1JPY in Million2JPY
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: March 2020 S1 2021 S1 2022 Q2 2022 S1 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 S1 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 S1 2024 Q3 2024 Q4
Net sales 1 15,555 13,533 8,746 20,530 7,615 6,706 8,307 8,951 17,258 8,904 7,294 9,661 8,400 18,061 9,323 8,716
EBITDA - - - - - - - - - - - - - - - -
EBIT 1 2,150 718 1,592 6,038 196 -1,739 1,126 1,484 2,610 797 -1,293 1,298 184 1,482 846 -1,028
Operating Margin 13.82% 5.31% 18.2% 29.41% 2.57% -25.93% 13.55% 16.58% 15.12% 8.95% -17.73% 13.44% 2.19% 8.21% 9.07% -11.79%
Earnings before Tax (EBT) -9,833 1,098 1,780 6,393 512 -1,510 1,714 1,886 3,600 618 -1,149 1,959 368 2,327 722 -
Net income 1 -10,766 976 1,367 5,019 345 -1,631 1,493 1,648 3,141 487 -1,392 1,887 215 2,102 599 -101
Net margin -69.21% 7.21% 15.63% 24.45% 4.53% -24.32% 17.97% 18.41% 18.2% 5.47% -19.08% 19.53% 2.56% 11.64% 6.42% -1.16%
EPS -190.9 17.30 - 89.07 6.180 - 26.62 - 56.32 9.100 - 34.62 - 38.54 10.97 -
Dividend per Share 13.00 10.00 - 15.00 - - - - 13.00 - - - - 13.00 - -
Announcement Date 11/8/19 11/11/20 11/9/21 11/9/21 2/8/22 5/13/22 8/5/22 11/8/22 11/8/22 2/8/23 5/12/23 8/4/23 11/8/23 11/8/23 2/14/24 -
1JPY in Million
Estimates

Balance Sheet Analysis

Fiscal Period: March 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - - -
Net Cash position 1 16,320 20,507 25,612 31,782 28,389 24,846 26,173 26,696
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 1,811 6,561 -634 - -300 -4,070 2,035 1,117
ROE (net income / shareholders' equity) 3.1% -16.3% 6.91% 5.7% 3.3% 3.8% 2.6% 3.9%
ROA (Net income/ Total Assets) 3.47% 5.35% 4.36% 7.43% 4.07% 2.9% 2.5% 3.9%
Assets 1 64,748 -202,485 97,714 50,220 54,960 89,655 70,400 69,231
Book Value Per Share 2 1,295 1,059 1,127 1,179 1,232 1,254 1,260 1,283
Cash Flow per Share 91.20 -161.0 88.50 81.80 61.30 - - -
Capex 1 1,182 1,668 1,891 2,050 1,874 4,850 1,700 1,700
Capex / Sales 4.16% 5.82% 6.84% 5.88% 5.6% 13.43% 4.93% 4.7%
Announcement Date 5/10/19 5/19/20 5/13/21 5/13/22 5/12/23 - - -
1JPY in Million2JPY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Seikagaku Corporation

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
737 JPY
Average target price
800 JPY
Spread / Average Target
+8.55%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
SEIKAGAKU CORPORATION Stock Seikagaku Corporation
-3.15% 255M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.83% 661B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+27.15% 566B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.76% 352B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.34% 332B
ABBVIE INC. Stock AbbVie Inc.
+3.00% 283B
ASTRAZENECA PLC Stock AstraZeneca PLC
+14.57% 231B
NOVARTIS AG Stock Novartis AG
+4.72% 200B
ROCHE HOLDING AG Stock Roche Holding AG
-9.37% 195B
AMGEN INC. Stock Amgen Inc.
-6.26% 145B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 4548 Stock
  4. Financials Seikagaku Corporation